Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1997-12-17
2000-09-05
Raymond, Richard L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
514254, 544295, 544364, 544371, A61K 31496, C07D40306
Patent
active
061143340
DESCRIPTION:
BRIEF SUMMARY
The present invention relates to novel substituted piperazine compounds which have affinity for 5-HT.sub.1A and/or .alpha..sub.1 and/or .alpha..sub.2 and/or D.sub.2 receptors, to processes for their preparation, to pharmaceutical compositions containing them and to their use in the treatment of central nervous system disorders, for example depression, anxiety, psychoses (for example schizophrenia), tardive dyskinesia, Parkinson's disease, obesity, hypertension, Tourette's syndrome, sexual dysfunction, drug addiction, drug abuse, cognitive disorders, Alzheimer's disease, senile dementia, obsessive-compulsive behaviour, panic attacks, social phobias, eating disorders and anorexia, cardiovascular and cerebrovascular disorders, non-insulin dependent diabetes mellitus, hyperglycaemia, constipation, arrhythmia, disorders of the neuroendocrine system, stress, prostatic hypertrophy, and spasticity.
The compound 4-allyl-2-(4-phenylpiperazin-1-ylmethyl)-5-(3-pyridyl)-1,2,4-triazol-3(2H, 4H)-thione is commercially available. Certain arylpiperazinylalkylenepyrazole compounds which have limited substitution in the pyrazole ring are disclosed generically in co-pending patent application PCT/EP95/02782 (WO9602246) as having affinity for D.sub.3 receptors. Such compounds are not included in the present invention.
The present invention comprises compounds of formula I ##STR2## including pharmaceutically acceptable salts thereof, in which
Ar represents phenyl, pyridyl, pyrimidinyl, naphthyl, 1,4-benzodioxin-5-yl, 1,4-benzodioxan-5-yl, benzo[b]furan-7-yl, 2,3-dihydrobenzo[b]furan-7-yl, benzo[b]thiophen-7-yl, 2,3-dihydrobenzo[b]thiophen-7-yl or chroman-8-yl each of which may be optionally substituted by one or more substituents selected from a) halo, b) an alkyl group containing 1 to 3 carbon atoms optionally substituted by one or more halo, c) an alkoxy group containing 1 to 3 carbon atoms optionally substituted by one or more halo, d) an alkylthio group, an alkylsulphinyl group or an alkylsulphonyl group each containing 1 to 3 carbon atoms optionally substituted by one or more halo, e) hydroxy, f) an acyloxy group containing 1 to 3 carbon atoms, g) a hydroxyalkyl group containing 1 to 3 carbon atoms, h) cyano, i) an alkanoyl group containing 1 to 6 carbon atoms, j) an alkoxycarbonyl group containing 2 to 6 carbon atoms, k) a carbamoyl group or a carbamoylmethyl group each optionally N-substituted by one or two alkyl groups each containing 1 to 3 carbon atoms, l) a sulphamoyl or sulphamoylmethyl group each optionally N-substituted by one or two alkyl groups each containing 1 to 3 carbon atoms, or m) an amino group optionally substituted by one or two alkyl groups each containing 1 to 3 carbon atoms;
A represents an alkylene chain containing 1 to 6 carbon atoms each of which may be optionally substituted by one or two alkyl groups each containing 1 to 3 carbon atoms; and
HET represents a group of formula a)-d) ##STR3## in which R.sub.1 represents hydroxy, an alkoxy group containing 1 to 3 carbon atoms, or an amino group optionally substituted by one or two alkyl groups each containing 1 to 3 carbon atoms;
R.sub.2 and R.sub.3 independently represent an alkyl group containing 1 to 6 carbon atoms optionally substituted by one or more halo, an alkenyl group containing 2 to 6 carbon atoms optionally substituted by one or more halo, a cycloalkyl group containing 3 to 6 carbon atoms, or phenyl, benzyl or a 5 or 6-membered heteroaryl group containing 1 to 3 heteroatoms selected from O,N and S wherein the phenyl, benzyl or heteroaryl group may be optionally substituted by one or more substituents selected from a) halo, b) an alkyl group containing 1 to 3 carbon atoms optionally substituted by one or more halo, c) an alkoxy group containing 1 to 3 carbon atoms optionally substituted by one or more halo, d) an alkylthio group, an alkylsulphinyl group or an alkylsulphonyl group each containing 1 to 3 carbon atoms optionally substituted by one or more halo, e) hydroxy, f) an acyloxy group containing 1 to 3 carbon atoms, g) a hydroxyalkyl
REFERENCES:
patent: 3729474 (1973-04-01), Mentrup et al.
patent: 4772604 (1988-09-01), Van Wijngaarden et al.
patent: 5194437 (1993-03-01), Peglion et al.
patent: 5242925 (1993-09-01), Boettcher et al.
patent: 5292739 (1994-03-01), Merce-Vidal et al.
patent: 5418237 (1995-05-01), Boettcher et al.
patent: 5712392 (1998-01-01), Thurrauf et al.
patent: 5760225 (1998-06-01), Yuan
Yan Tol et al, Nature, vol. 350, p. 610-614 (1991).
Drug Evaluations by AMA, p. 575-579 (1993).
Saxena, Pharmac. Ther. 66, p 339-368 (1995).
Cheetham Sharon Crawford
Kerrigan Frank
Watts John Paul
Knoll Aktiengesellschaft
Raymond Richard L.
LandOfFree
Piperazine derivatives as therapeutic agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Piperazine derivatives as therapeutic agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Piperazine derivatives as therapeutic agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2212383